ArticleDiabetes, obesity & metabolism2026
Barriers and Enablers to Diabetes Technologies Use Among Individuals With Type 1 Diabetes: A Scoping Review.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundAdvanced diabetes technologies are standard of care for people with Type 1 diabetes (T1D). However, inequitable access contributes to disparities in outcomes. PURPOSE: To characterise barriers and enablers to the use of advanced diabetes technologies among individuals with T1D and to synthesise these determinants using the Theoretical Domains Framework. DATA SOURCES: EMBASE, Cochrane, PubMed, and MEDLINE were systematically searched from January 1, 2000, to September 30, 2025. STUDY SELECTION: We included studies of any design examining characteristics associated with the use of insulin pumps, continuous glucose monitors (CGM), or automated insulin delivery (AID) in T1D. DATA EXTRACTION: Two reviewers independently screened and extracted data using a standardised tool. Determinants were categorised as non-modifiable or potentially modifiable barriers or enablers. Modifiable determinants were mapped to TDF domains to enable theory-informed synthesis. DATA SYNTHESIS: Of 3081 citations identified, 303 studies (1 864 469 participants) were included. Non-modifiable determinants most frequently associated with technology use included racial/ethnic minority status (n = 90), age (n = 53), sex (n = 36), and socioeconomic status (n = 40). Potentially modifiable determinants clustered primarily within six TDF domains, most commonly Environmental Context and Resources, Social Influences, Knowledge, Skills, Beliefs about Consequences, and Emotions. Within these domains, key barriers included financial constraints (n = 117), provider gatekeeping and clinic processes (n = 43), and physical burden or body image concerns (n = 41). Key enablers included supportive patient-provider relationships and shared decision-making (n = 42), patient education and knowledge of device benefits (n = 40), and proactive provider engagement (n = 24). LIMITATIONS: A large proportion of abstracts (35.3% overall; 70.6% of interventions), potential publication bias, exclusion of grey literature, predominance of US-based studies (62.4%), and few AID-only studies (6.9%) may limit generalisability.
conclusionsBarriers to diabetes technology use map to key TDF domains, with structural factors predominating. Multilevel interventions targeting health system processes, provider practices, and education are needed to improve equitable uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.